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Objectives This study sought to define the relationship between oxidative biomarkers, cardiovascular disease (CVD) risk fac-
tors, and inflammatory and thrombosis biomarkers.
Background Elevated levels of oxidized phospholipids (OxPL) on apolipoprotein B particles (apoB) represent a novel biomarker of
CVD. Previous studies suggest that an increase in OxPL/apoB reflects a positive response to statins and a low-fat diet.
Methods This study measured OxPL/apoB, lipoprotein (a) [Lp(a)], and oxidized low-density lipoprotein (OxLDL) biomarkers,
consisting of immunoglobulin (Ig)G and IgM autoantibodies to malondialdehyde (MDA)-low-density lipoprotein
(LDL) and IgG and IgM apoB-100 immune complexes (IC/apoB), at baseline and after 16 weeks of treatment
with atorvastatin 80 mg/day or placebo in 2,342 patients with acute coronary syndromes (ACS) enrolled in the
MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Results At baseline, potentially atheroprotective IgM autoantibodies and IgM IC/apoB were lower in male patients, dia-
betic patients, and patients 65 years of age. Patients with an LDL level greater than the median (122 mg/dl)
had higher levels of OxPL/apoB, Lp(a), and OxLDL biomarkers compared with those who had an LDL level less
than the median. Atorvastatin resulted in significantly larger changes in all biomarkers in female patients, pa-
tients age 65 years, patients with LDL cholesterol 122 mg/dl, nonsmokers, and nondiabetic patients (p 
0.0001 for all). In particular, a significant increase in OxPL/apoB in response to atorvastatin was noted in all 20
subgroups evaluated. Weak or no significant correlations were noted between all OxLDL biomarkers and
C-reactive protein, serum amyloid A, tissue plasminogen activator, interleukin-6, intercellular adhesion molecule,
vascular cell adhesion molecule, P-selectin, and E-selectin at randomization and 16 weeks.
Conclusions In patients with ACS, baseline levels of oxidative biomarkers varied according to specific CVD risk factors and
were largely independent of inflammatory biomarkers. Atorvastatin uniformly increased OxPL/apoB levels in all
subgroups studied. Future studies are warranted to assess whether the increase in OxPL/apoB levels reflects the
benefit of effective therapeutic interventions and prediction of new CVD events. (J Am Coll Cardiol 2009;53:
2186–96) © 2009 by the American College of Cardiology Foundation
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June 9, 2009:2186–96 OxLDL, Inflammation, and Statin Therapyhe MIRACL (Myocardial Ischemia Reduction with Aggres-
ive Cholesterol Lowering) study established that patients
resenting with acute coronary syndromes (ACS) treated with
torvastatin 80 mg had a reduction in recurrent ischemic
ardiovascular events over a 16-week period compared with
lacebo (1,2). A previous analysis of the MIRACL trial (3)
howed lower apolipoprotein B-100 (apoB) levels in patients
reated with atorvastatin than with placebo, but that the
emaining apoB particles in atorvastatin-treated patients were
ore enriched in oxidized phospholipids (OxPL), as measured
y antibody E06. Lipoprotein (a) [Lp(a)] binds and transports
06-detectable OxPL found on lipoproteins in human plasma
4–8). Accordingly, atorvastatin treatment in the MIRACL
rial resulted in an increase in Lp(a) levels paralleling the
ncrease in OxPL/apoB and reduction in clinical events. In
ormal subjects as well as in clinically stable patients with
yslipidemia, an increase in OxPL/apoB levels also occurred in
esponse to low-fat diets (9) or statin therapy (10–12). A
imilar increase has been seen in rabbits and cynomolgus
onkeys with pre-existing atherosclerosis, which were subse-
uently placed on low-fat diets (13). Based on these observa-
ions, we previously hypothesized that an increase in OxPL/
poB levels after therapeutic interventions may be a biomarker
f plaque stabilization and early atherosclerosis regression.
Although many epidemiological studies show broad associ-
tions between oxidized low-density lipoprotein (OxLDL)
iomarkers and cardiovascular disease (CVD), little informa-
ion exists regarding the interaction of clinical characteristics,
nflammatory biomarkers, and statin therapy on indicators of
xLDL (14–17). In a previous analysis of the MIRACL trial,
e evaluated the overall effect of high-dose atorvastatin in
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nique changes in a variety of ox-
dative biomarkers in response to
torvastatin (1,2). In particular, we
oted significant increases in
xPL/apoB that mirrored the ef-
ect of atorvastatin. In the current
nalysis, we evaluated the inter-
elationships between a compre-
ensive panel of oxidative biomar-
ers and clinical and demographic
escriptors, lipid parameters, and
nflammatory biomarkers to assess
he impact of atorvastatin therapy
n specific and large subgroups of
atients. This investigation aimed
o gain insights into the potential
echanisms of the early benefit of
tatin therapy.
ethods
tudy design and patient sample. The MIRACL trial
nrolled 3,086 patients with unstable angina or non-Q-
ave acute myocardial infarction between 24 and 96 h after
ospital admission at 122 centers in 19 countries. Patients
ere randomly assigned to double-blind treatment with
torvastatin 80 mg/day or placebo for 16 weeks. The
rimary efficacy measure was the time to first occurrence of
eath, nonfatal acute myocardial infarction, cardiac arrest
ith resuscitation, or worsening angina with new objective
vidence of ischemia and requiring emergency re-
ospitalization (1). Blood samples for biomarker analysis
ere collected at baseline and at 16 weeks of randomized
reatment. Blood was collected in ethylenediaminetetraace-
ic acid and stored at 70°C. Of 2,739 patients who
urvived to complete the 16-week trial, 2,342 had baseline
nd week-16 blood samples available and served as the
ohort for the present analysis.
Seven hundred forty-four participants in the trial were
ot included in this analysis because of death before 16-
eek follow-up or missing laboratory samples. Of the 2,342
atients included, 10.6% had a nonfatal primary end point
n the atorvastatin group and 12.2% in the placebo group
uring the 16-week follow-up period. This corresponds to a
3% relative risk reduction with atorvastatin. In the entire
IRACL study population, fatal and nonfatal primary end
oint events occurred in 14.8% and 17.6% of the atorvasta-
in and placebo groups, respectively, corresponding to a 16%
elative risk reduction with atorvastatin. The incidence of
ecurrent events and the relative risk reduction with
torvastatin were lower in the cohort of the present
nalysis than the entire MIRACL study population
ecause patients who died in the follow-up period did not
ave a 16-week blood sample and therefore are not
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
apoB  apolipoprotein
B-100
CI  confidence interval
CVD  cardiovascular
disease
IC/apoB  apolipoprotein
B-immune complexes
Ig  immunoglobulin
Lp(a)  lipoprotein (a)
MDA  malondialdehyde
OxLDL  oxidized low-
density lipoprotein
OxPL  oxidized
phospholipidsepresented in this analysis.
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OxLDL, Inflammation, and Statin Therapy June 9, 2009:2186–96etermination of OxPL/apoB, Lp(a), and apoB levels.
evels of OxPL/apoB, Lp(a), and apoB were measured as
reviously described (3). The OxPL/apoB measure re-
ects the content of OxPL on apoB particles, which
rimarily consist of OxPL detectable with murine mono-
lonal antibody E06 on Lp(a), where Lp(a) is not necessarily
xidized but acts as carrier of such OxPL. Therefore,
xPL/apoB is not necessarily a biomarker of OxLDL per
e, but reflects the biological capacity of Lp(a) to bind and
ransport OxPL.
etermination of OxLDL biomarkers: immunoglobulin
Ig)G and IgM autoantibodies to malondialdehyde
MDA)-LDL and IgG and IgM ApoB immune com-
lexes (IC/apoB). IgG and IgM autoantibodies to MDA-
DL and IgG and IgM IC/apoB were measured as previ-
usly described (3).
etermination of inflammatory biomarker levels. High-
ensitivity C-reactive protein, serum amyloid A, and
nterleukin-6 were measured as previously described (18).
issue plasminogen activator, intercellular adhesion mole-
ule, vascular cell adhesion molecule, P-selectin, and
-selectin were measured by enzyme-linked immuno-
orbent assay kits from R&D Systems (Minneapolis,
innesota).
tatistical analysis. Because the baseline and week 16
istributions of the OxLDL markers were positively
kewed, log-transformed values were used in the statistical
odels and analyses and antilog-transformed for descriptive
tatistics yielding geometric means and 95% confidence
ntervals (CIs) for baseline, week 16, and percent change
rom baseline to week 16. Inferential analyses included
aired-sample t tests for within-treatment group differences
n markers at baseline versus week 16, and independent-
ample t tests for between-treatment group differences in
arkers at week 16 and between-treatment group differ-
nces in absolute change from baseline to week 16. All
aired- and independent-sample t tests were based on
og-transformed makers. Spearman correlations (based on
he raw data) were calculated to summarize the relationship
etween OxLDL, lipid, and inflammatory biomarkers.
tatistical significance was defined as p  0.001 to
ccount for multiple comparisons. All data management
nd statistical analyses were carried out under the super-
ision of Pfizer, Inc.
esults
atient characteristics. Table 1 shows the baseline char-
cteristics of the study population. The study cohort con-
isted of 1,549 male patients and 793 female patients, 1,114
atients 65 years of age and 1,228 patients 65 years of
ge, 1,612 patients with hypertension, 526 patients with
iabetes mellitus, and 666 current smokers. The presenting
ymptom was unstable angina in 1,061 patients and non–
-wave myocardial infarction in 1,281 patients. There were lo statistical differences in baseline characteristics between
he atorvastatin and placebo groups.
elationship of baseline levels of OxPL/apoB, Lp(a), and
xLDL biomarkers to various cardiovascular risk factors
ccording to median levels of lipid parameters. Table 2
hows the mean (95% CI) levels of the various parameters
easured according to specific subgroups of patients and
ccording to less than or greater than median levels of lipid
arameters. The OxPL/apoB and Lp(a) levels were highest
n patients age 65 years and nondiabetic patients. In
eneral, IgM autoantibodies and ICs tended to be higher in
raditionally lower-risk subgroups and IgG autoantibodies
nd ICs higher in subgroups traditionally at higher risk. All
xidative variables tended to be higher in patients with
DL greater than median (122 mg/dl) and apoB greater
han median (131 mg/dl).
hanges in OxPL/apoB and Lp(a) according to sub-
roups in response to atorvastatin versus placebo. In a
revious analysis (3), we reported that atorvastatin, com-
ared with placebo, resulted in significant increases in
xPL/apoB (9.5% vs.3.9%, p 0.0001) and Lp(a) (8.8%
s. 0.7%, p  0.0001) over the 16-week treatment period.
urthermore, IgM IC/apoB increased in the atorvastatin
roup but decreased in the placebo group at 16 weeks
15.4% vs. 9.3%, p  0.0001) and were associated with
educed risk of subsequent events.
In the current analysis, we evaluate changes in these OxLDL
iomarkers in specific subgroups of patients. Figure 1 shows
reatment effects of atorvastatin versus placebo in specific
ubgroups, as well as within-subgroup differences in OxPL/
poB and Lp(a) in both the placebo and the atorvastatin
roups individually. There was a consistently and signifi-
antly higher increase in OxPL/apoB in all 12 subgroups of
ardiovascular risk factors and across all 8 subgroups of
aseline Characteristicsf the 2,342 Study Subjects
Table 1 Baseline Characteristicsof the 2,342 Study Subjects
Characteristic
Placebo
(n  1,191)
Atorvastatin
(n  1,151)
Age, mean (SD), yrs 64 (11) 65 (11)
Men, n (%) 797 (67) 752 (65)
Presenting syndrome, n (%)
Unstable angina 534 (45) 527 (46)
Non–Q-wave myocardial infarction 657 (55) 624 (54)
Past myocardial infarction, n (%) 288 (24) 269 (23)
Prior coronary revascularization, n (%) 131 (11) 109 (9)
Hyperlipidemia, n (%) 408 (34) 421 (35)
Hypertension, n (%) 636 (53) 629 (55)
Diabetes mellitus type II, n (%) 280 (24) 251 (22)
Total cholesterol, mean (SD), mg/dl 207 (37) 206 (38)
LDL cholesterol, mean (SD), mg/dl 124 (33) 124 (34)
HDL cholesterol, mean (SD), mg/dl 46 (12) 47 (12)
Triglycerides, mean (SD), mg/dl 185 (90) 182 (86)
DL  high-density lipoprotein; LDL  low-density lipoprotein.ipoproteins dichotomized by median levels in response to
Baseline Levels of OxLDL Biomarkers [Mean (95% CI)] in Patients With VariousC rdiovascular Risk Factors and According to Median Lipid Profile Values on Presentation
Table 2 Baseline Levels of OxLDL Biomarkers [Mean (95% CI)] in Patients With VariousCardiovascular Risk Factors and According to Median Lipid Profile Values on Presentation
Variable OxPL/apoB Lp(a) MDA-LDL IgG MDA-LDL IgM IC/apoB IgG IC/apoB IgM
Sex
Male 10,125 (9,845–10,412) 11.7 (11.0–12.3) 4,519 (4,401–4,641) 9,437 (9,168–9,714) 8,397 (8,167–8,632) 3,410 (3,290–3,535)
Female 10,013 (9,632–10,410) 12.7 (11.7–13.8) 4,303 (4,119–4,494) 11,446 (11,002–11,909) 8,128 (7,801–8,468) 3,582 (3,410–3,763)
p Value 0.65 0.08 0.059 <0.0001 0.18 0.12
Age, yrs
65 10,365 (10,022–10,721) 12.5 (11.7–13.3) 4,352 (4,202–4,506) 10,328 (9,994–10,673) 8,299 (8,029–8,579) 3,888 (3,741–4,041)
65 9,841 (9,545–10,146) 11.6 (10.9–12.4) 4,531 (4,396–4,670) 9,850 (9,521–10,189) 8,310 (8,049–8,579) 3,125 (2,997–3,260)
p Value 0.025 0.13 0.086 0.049 0.96 <0.0001
Hypertension
Yes 10,060 (9,790–10,338) 11.8 (11.2–12.5) 4,475 (4,350–4,605) 10,117 (9,831–10,410) 8,510 (8,274–8,752) 3,443 (3,321–3,568)
No 10,062 (9,658–10,483) 12.2 (11.2–13.3) 4,392 (4,223–4,567) 9,991 (9,572–10,428) 7,911 (7,600–8,234) 3,536 (3,366–3,714)
p Value 0.99 0.55 0.44 0.63 0.004 0.39
Diabetes mellitus
Yes 9,571 (9,143–10,019) 10.9 (9.9–11.9) 4,480 (4,268–4,702) 9,511 (9,037–10,010) 8,626 (8,207–9,066) 3,382 (3,181–3,595)
No 10,208 (9,946–10,478) 12.3 (11.7–13.0) 4,441 (4,326–4,559) 10,250 (9,979–10,529) 8,234 (8,023–8,451) 3,497 (3,384–3,615)
p Value 0.019 0.029 0.76 0.001 0.099 0.34
Active smoking
Yes 10,207 (9,775–10,658) 12.3 (11.3–13.4) 4,558 (4,370–4,755) 10,066 (9,622–10,530) 8,301 (7,936–8,683) 3,555 (3,372–3,749)
No 10,003 (9,740–10,272) 11.8 (11.2–12.5) 4,407 (4,287–4,530) 10,082 (9,805–10,369) 8,330 (8,109–8,556) 3,437 (3,320–3,559)
p Value 0.43 0.46 0.19 0.95 0.89 0.30
Inclusion event
Non–Q-wave MI 9,965 (9,663–10,277) 12.0 (11.2–12.7) 4,232 (4,098–4,371) 9,870 (9,552–10,198) 7,864 (7,633–8,103) 3,404 (3,273–3,541)
Unstable angina 10,236 (9,898–10,585) 12.0 (11.3–12.9) 4,716 (4,566–4,870) 10,327 (9,980–10,686) 8,869 (8,562–9,187) 3,545 (3,397–3,700)
p Value 0.25 0.86 <0.0001 0.06 <0.0001 0.17
Apo B-100, mg/dl
131 9,998 (9,685–10,320) 11.8 (11.1–12.6) 4,296 (4,153–4,444) 9,815 (9,492–10,149) 7,947 (7,690–8,212) 3,389 (3,252–3,532)
131 10,176 (9,849–10,515) 12.3 (11.5–13.1) 4,592 (4,452–4,737) 10,341 (9,998–10,696) 8,703 (8,428–8,988) 3,551 (3,408–3,699)
p Value 0.45 0.44 0.004 0.031 0.0001 0.12
Total cholesterol, mg/dl
206 9,914 (9,601–10,237) 11.6 (10.9–12.4) 4,332 (4,200–4,468) 9,752 (9,424–10,092) 8,141 (7,873–8,418) 3,430 (3,291–3,575)
206 10,208 (9,886–10,541) 12.3 (11.5–13.1) 4,569 (4,416–4,728) 10,411 (10,073–10,760) 8,504 (8,239–8,778) 3,512 (3,371–3,659)
p Value 0.21 0.24 0.023 0.97 0.06 0.42
LDL cholesterol, mg/dl
122 9,655 (9,356–9,963) 10.8 (10.2–11.6) 4,209 (4,066–4,357) 9,816 (9,488–10,156) 7,781 (7,529–8,041) 3,360 (3,224–3,503)
122 10,507 (10,165–10,860) 13.3 (12.5–14.2) 4,711 (4,568–4,858) 10,348 (10,004–10,704) 8,901 (8,619–9,194) 3,584 (3,438–3,736)
p Value 0.0003 <0.0001 <0.0001 0.031 <0.0001 0.031
HDL cholesterol, mg/dl
45 9,700 (9,398–10,012) 10.7 (10.0–11.4) 4,410 (4,273–4,550) 9,914 (9,582–10,258) 8,494 (8,217–8,780) 3,565 (3,426–3,708)
45 10,416 (10,085–10,759) 13.3 (12.5–14.2) 4,493 (4,344–4,646) 10,241 (9,907–10,587) 8,164 (7,906–8,430) 3,388 (3,247–3,535)
p Value 0.002 <0.0001 0.43 0.18 0.092 0.086
Triglycerides, mg/dl
164 10,633 (10,283–10,996) 13.8 (12.9–14.7) 4,583 (4,427–4,744) 10,082 (9,741–10,436) 8,875 (8,581–9,179) 3,470 (3,324–3,622)
164 9,533 (9,248–9,826) 10.4 (9.8–11.1) 4,324 (4,194–4,458) 10,074 (9,748–10,411) 7,815 (7,576–8,062) 3,472 (3,337–3,611)
p Value <0.0001 <0.0001 0.014 0.97 <0.0001 0.99
For OxPL/apoB, IgG, and IgM, IgG IC/apoB and autoantibodies to MDA-LDL, units are in relative light units. Lp(a) units are mg/dl. The p values in bold represent significant changes defined as p  0.001.
apoB  apolipoprotein B-100; CI  confidence interval; HDL  high-density lipoprotein; IC/apoB  apolipoprotein B-immune complexes; Ig  immunoglobulin; LDL  low-density lipoprotein; Lp(a)  lipoprotein (a); MDA  malondialdehyde; MI  myocardial infarction;
OxLDL  oxidized low-density lipoprotein; OxPL  oxidized phospholipids; OxPL/apoB  oxidized phospholipids as measured by antibody E06. 2189
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OxLDL, Inflammation, and Statin Therapy June 9, 2009:2186–96Figure 1 Change in OxPL/apoB and Lp(a) Levels in Various Subgroups in Response to Atorvastatin
The panels represent the mean percent change (95% confidence interval) from baseline to week 16 in OxPL/apoB (A) and Lp(a) (B) levels in the various subgroups
according to treatment with atorvastatin versus placebo. The p values listed in the right margin in each panel represent differences between placebo versus atorvastatin
in the various subgroups. ‡Within-group mean percent changes from baseline to week 16 in the placebo or atorvastatin groups individually (‡p  0.001). HDL  high-
density lipoprotein; Lp(a)  lipoprotein(a); LDL  low-density lipoprotein; MI  myocardial infarction; OxPL/apoB  oxidized phospholipids as measured by antibody E06.
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June 9, 2009:2186–96 OxLDL, Inflammation, and Statin Therapytorvastatin therapy compared with placebo (Fig. 1A).
hanges in Lp(a) were similar to changes in OxPL/apoB,
xcept that the changes were not as uniform as seen with
xPL/apoB (Fig. 1B).
Evaluating within-group changes (p values for within-group
hanges in Figure 1 are represented by the symbol ‡ next to
he numerical data) in the atorvastatin group alone, in-
reases in OxPL/apoB (ranging from 4.8% to 12.4%) from
aseline to 16 weeks were noted in all subgroups (Fig. 1A).
imilarly, in response to atorvastatin, Lp(a) increased in all
ubgroups (range 3.7% to 18.1%), except in male patients,
urrent smokers, those with triglyceride levels less than the
edian, and those with total cholesterol levels greater than
he median (Fig. 1B). In contrast, within-group changes in
he placebo-treated group showed mainly reductions or no
hanges in OxPL/apoB or Lp(a) over the 16-week obser-
ation period.
hanges in autoantibodies to MDA-LDL and ICs ac-
ording to subgroups in response to atorvastatin versus
lacebo. Over the 16-week treatment period, IgG IC/
poB increased in all subgroups of the atorvastatin group
range 3% to 20%), but in none of the subgroups of the
lacebo group. For IgM IC/apoB, significant increases were
oted in subgroups of both the placebo and atorvastatin
roups. For both IgG and IgM MDA-LDL autoantibody
evels, highly significant increases (approximately 5% to
5%, p  0.001 for all) were noted in all subgroups of both
reatment groups. As opposed to subgroup analysis for
xPL/apoB and Lp(a), homogeneity was not present
mong subgroups of each treatment group in these re-
ponses (Table 3).
orrelations among OxLDL biomarkers at randomiza-
ion. Table 4 shows the correlations between OxPL/apoB,
p(a), and OxLDL biomarkers at the baseline time point at
andomization. The OxPL/apoB levels correlated strongly
ith Lp(a) (r  0.68, p  0.0001) and weakly, but
ignificantly, with all other indirect OxLDL measures. All
gG and IgM OxLDL biomarkers correlated with each
ther modestly. Similar correlations were noted at the end
f the 16-week study period (data not shown).
orrelations between OxLDL biomarkers and inflam-
atory biomarkers at randomization. Table 5 shows the
orrelation analysis between OxPL/apoB, Lp(a), OxLDL
iomarkers, lipid parameters, and inflammatory and throm-
osis biomarkers. Modest to weak, but statistically signifi-
ant, correlations were noted between total cholesterol and
DL cholesterol (LDL-C) and essentially all oxidative
iomarkers. Significant positive and negative correlations
ere noted between several of the oxidative biomarkers and
nflammatory markers, but most of these were quite weak.
f interest, OxPL/apoB and Lp(a) did not correlate with
igh-sensitivity C-reactive protein, serum amyloid A, or
nterleukin-6. Overall similar findings were noted at the end
f the 16-week study period (data not shown). piscussion
he most remarkable finding of this analysis of the MIRACL
tudy, encompassing a large cohort of patients with ACS in
placebo-controlled trial, was that the increase in OxPL/
poB levels in response to atorvastatin was consistently and
ignificantly increased in all 12 subgroups of CVD risk
actors and across all 8 subgroups of lipoproteins. Based on
revious studies in experimental animal models, and in
bservations in smaller cohorts of patients on diets or
tatins, we previously suggested that an increase in OxPL/
poB levels in response to intervention may reflect plaque
egression and/or stabilization (13,19,20). These results
trongly argue that future studies are warranted to assess
hether the increase in OxPL/apoB will be a biomarker of
n effective response to therapeutic interventions and pre-
iction of new events, either in the setting of ACS or in
ore stable patients over a longer time interval.
elationship of OxPL/apoB levels to statin therapy and
ow-fat diets. The effect of therapeutic interventions on
iomarkers of OxLDL in humans is now undergoing detailed
valuation. The increase in OxPL/apoB in response to atorva-
tatin was initially noted in the MIRACL study (3). Subse-
uently, several additional studies have validated this observa-
ion using various doses of pravastatin (10–12) or atorvastatin
11,12) and also in young women (9) or children with familial
ypercholesterolemia consuming low-fat diets (10), showing a
% to 48% increases in OxPL/apoB. In cynomolgus monkeys
nd New Zealand White rabbits with established atheroscle-
osis, 50% to 100% increases in OxPL/apoB were noted
ollowing regression diets. These increases were associated with
near-complete depletion of OxPL and malondialdehyde
pitopes and other measures of oxidative stress in aortic
therosclerotic lesions, which coincided with concomitant
vidence of plaque stabilization as indicated by loss of plaque
acrophages and increased smooth muscle cell and collagen
ontent (13,19,20). Similar observations showing reduced
xidative stress and inflammation with concomitant plaque
tabilization were noted in human carotid endarterectomy
laques after 3 months of treatment with pravastatin (21).
herefore, this evidence supporting the utility of oxidation-
pecific epitopes to monitor biologically relevant changes in
therosclerotic lesions and in plasma after therapeutic inter-
entions provides a strong rationale for further study. It
ears emphasis that the OxPL/apoB measure only detects
xPL on apoB particles, and primarily on Lp(a), and that it
oes not detect OxPL in plasma or OxPL not recognized by
ntibody E06 (22).
In the current study, OxPL/apoB and Lp(a) did not
hange significantly in the placebo group or any placebo
ubgroups. Overall in the MIRACL trial, reduction of
ardiovascular events was not related to any significant
nteraction of treatment assignment with age, gender, dia-
etes, or current smoking, although the power of the study
ay limit the conclusions of such analyses. We havereviously shown increases in OxPL/apoB and Lp(a) as
Within-Group Changes in the Mean Percent Change From Baselinein Immune Complex and Autoantibodi s to MDA-LDL [Me n (95% CI)]
Table 3 Within-Group Changes in the Mean Percent Change From Baselinein Immune Complexes and Autoantibodies to MDA-LDL [Mean (95% CI)]
IC/apoB IgG IC/apoB IgM MDA-LDL IgG MDA-LDL IgM
Variable Placebo Atorvastatin Placebo Atorvastatin Placebo Atorvastatin Placebo Atorvastatin
Sex
Male 1.1 (4.6 to 2.4) 8.7* (5.0 to 12.6) 11.1* (7.5 to 14.7) 15.6* (11.8 to 19.4) 10.9* (8.5 to 13.4) 12.4* (9.9 to 14.9) 12.4* (10.1 to 14.6) 8.8* (6.5 to 11.2)
Female 3.0 (7.6 to 1.8) 11.4* (6.1 to 17.0) 5.8 (0.2 to 11.7) 15.6* (10.7 to 20.7) 10.6* (7.2 to 14.3) 18.4* (12.5 to 24.7) 7.9* (5.3 to 10.6) 9.4* (6.3 to 12.6)
Age, yrs
65 0.1 (4.0 to 3.9) 9.7* (5.0 to 14.6) 11.7* (7.9 to 15.7) 14.4* (10.2 to 18.7) 12.2* (9.4 to 15.2) 12.5* (8.1 to 17.1) 13.1* (10.7 to 15.6) 8.1* (5.4 to 10.7)
65 3.3 (7.1 to 0.7) 9.7* (5.6 to 13.9) 7.0 (2.4 to 11.7) 16.7* (12.5 to 21.0) 9.5* (6.7 to 12.4) 16.1* (13.2 to 19.1) 8.7* (6.3 to 11.2) 9.8* (7.2 to 12.5)
Hypertension
Yes 3.4 (6.7 to0.0) 9.1* (5.5 to 12.7) 8.6* (4.7 to 12.6) 14.7* (11.1 to 18.5) 10.1* (7.7 to 12.6) 13.9* (10.6 to 17.3) 10.5* (8.5 to 12.6) 9.2* (6.9 to 11.6)
No 2.0 (3.0 to 7.2) 10.8* (4.6 to 17.1) 11.1* (6.5 to 15.9) 17.7* (12.6 to 23.1) 12.8* (9.1 to 16.5) 16.0* (12.1 to 20.0) 11.7* (8.5 to 15.1) 8.8* (5.8 to 11.9)
Diabetes
Yes 5.3 (10.8 to 0.5) 16.6* (9.9 to 23.8) 8.3 (2.2 to 14.8) 21.2* (14.3 to 28.6) 9.6* (5.3 to 14.1) 13.5* (8.7 to 18.5) 11.7* (8.1 to 15.5) 10.5* (6.3 to 14.8)
No 0.6 (3.8 to 2.7) 7.7* (4.2 to 11.3) 9.7* (6.3 to 13.3) 14.1* (10.8 to 17.5) 11.4* (9.1 to 13.7) 14.8* (11.7 to 17.9) 10.7* (8.7 to 12.7) 8.7* (6.6 to 10.8)
Active smoking
Yes 4.4 (0.9 to 9.9) 8.7 (3.1 to 14.6) 14.3* (9.0 to 19.8) 17.8* (11.9 to 24.1) 15.4* (11.3 to 19.6) 14.9* (11.1 to 18.8) 17.1* (13.5 to 20.9) 14.9* (11.0 to 19.0)
No 4.2 (7.4 to0.8) 9.9* (6.2 to 13.7) 7.5* (3.8 to 11.3) 14.7* (11.3 to 18.2) 9.2* (6.9 to 11.5) 14.4* (11.0 to 17.8) 8.5* (6.5 to 10.4) 6.9* (4.8 to 9.0)
Inclusion event
Non–Q-wave MI 2.4 (1.4 to 6.3) 12.6* (8.4 to 16.9) 15.5* (11.5 to 19.6) 18.0* (13.9 to 22.2) 16.3* (13.5 to 19.2) 17.9* (13.8 to 22.1) 13.8* (11.4 to 16.2) 10.2* (7.6 to 12.8)
Unstable angina 6.6 (10.5 to2.5) 6.3 (1.8 to 11.0) 2.2 (2.3 to 6.8) 12.9* (8.6 to 17.3) 4.4* (1.64 to 7.3) 10.5* (7.5 to 13.7) 7.4* (4.9 to 9.9) 7.7* (5.0 to 10.4)
Total cholesterol, mg/dl
206 0.9 (2.9 to 4.9) 16.4* (11.7 to 21.2) 13.0* (8.8 to 17.4) 18.8* (14.4 to 235) 15.4* (12.4 to 18.4) 18.6* (15.6 to 21.6) 13.4* (10.7 to 16.2) 10.9* (8.1 to 13.8)
206 4.3 (8.1 to0.2) 3.0 (1.0 to 7.19) 6.1 (1.7 to 10.6) 12.4* (8.4 to 16.4) 6.9* (4.1 to 9.6) 10.5* (6.3 to 14.8) 8.6* (6.4 to 10.8) 7.2* (4.9 to 9.7)
LDL cholesterol, mg/dl
122 2.4 (1.6 to 6.6) 16.0* (11.4 to 20.7) 13.5* (8.7 to 18.6) 19.5* (15.2 to 24.0) 16.9* (13.9 to 19.9) 19.8* (15.4 to 24.5) 13.5* (10.8 to 16.2) 10.3* (7.7 to 13.1)
122 5.8 (9.6 to1.8) 3.16 (0.9 to 7.4) 5.6 (1.8 to 9.5) 11.7* (7.6 to 16.0) 5.7* (3.0 to 8.5) 9.1* (6.2 to 12.0) 8.7* (6.39 to 11.0) 8.0* (5.4 to 10.7)
HDL cholesterol, mg/dl
45 1.3 (2.7 to 5.4) 9.2* (4.7 to 13.8) 10.3* (6.2 to 14.5) 13.7* (9.6 to 17.9) 11.6* (8.6 to 14.6) 12.8* (9.8 to 15.9) 11.4* (8.8 to 14.1) 7.9* (5.2 to 10.8)
45 4.7 (8.5 to0.7) 9.8* (5.6 to 14.1) 8.5* (4.1 to 13.2) 17.2* (12.9 to 21.6) 10.4* (7.6 to 13.2) 15.9* (11.7 to 20.2) 10.4* (8.1 to 12.8) 10.1* (7.6 to 12.7)
Triglycerides, mg/dl
164 6.6 (10.4 to2.6) 6.4 (0.2 to 10.7) 5.8* (1.4 to 10.4) 14.9* (10.9 to 19.0) 9.5* (6.9 to 12.3) 16.2* (12.0 to 20.6) 11.0* (8.5 to 13.5) 10.7* (8.3 to 13.3)
164 3.1 (0.9 to 7.2) 12.8* (8.3 to 17.5) 12.9 (8.8 to 17.2) 16.3* (11.9 to 20.9) 12.3* (9.3 to 15.4) 12.8* (9.8 to 16.0) 10.8* (8.38 to 13.3) 7.5* (4.7 to 10.3)
*p  0.001 for within-group comparison of baseline and 16-week levels.
MI  myocardial infarction; other abbreviations as in Table 1.
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June 9, 2009:2186–96 OxLDL, Inflammation, and Statin Therapycute phase reactants after myocardial infarction that can
emain elevated for 6 months (6). Unfortunately, the current
ata do not allow us to test whether increases in OxPL/
poB or Lp(a) in the atorvastatin group relate to decreased
ardiovascular risk, because one cannot use values of bio-
arkers at week 16 or changes in biomarkers between
aseline and week 16 to determine a relation to events
efore week 16. To validate the hypothesis that an increase
n OxPL/apoB can serve as a biomarker of efficacious
herapy, future studies in patients would need to determine
change in OxPL/apoB in response to therapeutic inter-
entions, follow up subjects for events, and assess whether
he change in OxPL/apoB was a predictor of the observed
enefit. Alternatively one may document loss of oxidation-
orrelations Among OxLDL Biomarkers at Randomization
Table 4 Correlations Among OxLDL Biomarkers at Randomizati
OxPL/apoB Lp(a) IC/ap
OxPL/apoB — r 0.68
p 0.0001
r 0
p 0
Lp(a) — — r
p 0
IC/apoB IgG — — —
IC/apoB IgM — — —
MDA-LDL IgG — — —
MDA-LDL IgM — — —
alues are Spearman rank correlations: coefficient: r, p value.
Abbreviations as in Table 1.
orrelation Between OxLDL Biomarkers With Lipid Parameters and
Table 5 Correlation Between OxLDL Biomarkers With Lipid Par
OxPL/apoB Lp (a) MDA
ApoB-100 r 0.01
p 0.80
r 0.01
p 0.73
r
p
LDL cholesterol r 0.08
p 0.0002
r 0.11
p 0.0001
r
p
HDL cholesterol r 0.06
p 0.004
r 0.10
p 0.0001
r
p
Triglycerides r0.12
p 0.0001
r0.16
p 0.0001
r
p
Total cholesterol r 0.04
p 0.08
r 0.05
p 0.027
r
p
hs-CRP r0.02
p 0.39
r 0.03
p 0.10
r
p
SAA r0.04
p 0.07
r 0.02
p 0.27
r
p
IL-6 r0.03
p 0.16
r 0.01
p 0.49
r
p
t-PA r0.01
r 0.74
r0.06
p 0.008
r
p
ICAM r0.08
p 0.0001
r0.07
p 0.002
r
p
VCAM r0.06
p 0.002
r0.04
p 0.06
r
p
P-selectin r0.02
p 0.48
r0.02
p 0.35
r
p
alues are Spearman rank correlations: coefficient: r, p value.
Hs-CRP  high-sensitivity C-reactive protein; ICAM  intercellular adhesion molecule; IL  interleukin
olecule; other abbreviations as in Table 1.pecific epitopes in the vessel wall, as has been recently
ocumented in mice using magnetic resonance techniques
23), in conjunction with an increase in plasma levels of
xPL/apoB. In contrast to studies in ACS in which these
iomarkers may be affected by the severity of the underlying
resentation, studies in stable subjects without pre-existing
VD have shown a strong predictive value of OxPL/apoB
nd Lp(a) measures (24,25).
elationship of OxPL/apoB, Lp(a), and OxLDL bio-
arkers to demographic and lipid variables. This analysis
f the MIRACL study further shows significant baseline
ifferences in levels of OxPL/apoB, Lp(a), and OxLDL
iomarkers among a variety of subgroups in patients pre-
enting with ACS. For example, IgM autoantibodies and
IC/apoB IgM MDA-LDL IgG MDA-LDL IgM
r 0.15
p 0.0001
r 0.09
p 0.0001
r 0.05
p 0.019
r 0.09
p 0.0001
r 0.01
p 0.75
r 0.05
p 0.009
r 0.31
p 0.0001
r 0.47
p 0.0001
r 0.11
p 0.0001
— r 0.20
p 0.0001
r 0.65
p 0.0001
— — r 0.19
p 0.0001
— — —
mmatory Markers at Randomization
ers and Inflammatory Markers at Randomization
gG MDA-LDL IgM IC/apoB IgG IC/apoB IgM
1
r 0.06
p 0.007
r 0.12
p 0.0001
r 0.05
p 0.011
1
r 0.06
p 0.007
r 0.14
p 0.0001
r 0.07
p 0.001
r 0.03
p 0.19
r0.05
p 0.030
r0.04
p 0.08
1 r 0.02
p 0.45
r0.12
p 0.0001
r0.01
p 0.73
r 0.07
p 0.001
r 0.05
p 0.017
r 0.04
p 0.053
r0.05
p 0.015
r0.01
p 0.80
r0.06
p 0.007
2
r0.06
p 0.007
r0.02
p 0.36
r0.07
p 0.0006
r0.04
p 0.07
r 0.07
p 0.002
r0.06
p 0.006
r 0.02
p 0.42
r0.06
p 0.006
r0.02
p 0.33
r 0.09
p 0.0001
r0.01
p 0.93
r 0.04
p 0.035
1
r 0.06
p 0.006
r 0.02
p 0.42
r 0.02
p 0.24
r 0.01
p 0.64
r 0.04
p 0.05
r 0.03
p 0.16on
oB IgG
.15
.0001
0.08
.0002Infla
amet
-LDL I
0.08
0.000
0.10
0.000
0.00
0.91
0.06
0.003
0.06
0.006
0.06
0.003
0.08
0.000
0.04
0.07
0.03
0.20
0.03
0.13
0.12
0.000
0.01
0.64; SAA  serum amyloid A; t-PA  tissue plasminogen activator, VCAM  vascular cell adhesion
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OxLDL, Inflammation, and Statin Therapy June 9, 2009:2186–96gM IC/apoB, which have been previously suggested to be
theroprotective (3,26,27), were lower in groups tradition-
lly associated with higher CVD risk, such as male patients,
iabetic patients, and older patients. In contrast, patients
ith LDL-C above the median level of 122 mg/dl tended to
ave higher levels of most oxidative biomarkers. The effect
f atorvastatin on OxPL/apoB and OxLDL biomarkers was
enerally stronger in traditionally lower-risk subgroups,
uch as female patients, younger patients, nonsmokers,
ondiabetic patients, and patients with lower LDL-C.
The OxPL/apoB and Lp(a) levels tended not to be
ssociated with other CVD risk factors. The OxPL/apoB
nd Lp(a) levels were not correlated with apoB-100, but
ere higher in patients with LDL-C greater than the
edian (122 mg/dl), HDL-C 45 mg/dl, and triglycerides
164 mg/dl. It is well appreciated that the OxPL/apoB
easure correlates with Lp(a), but this is dependent on the
polipoprotein(a) isoform size as measured by kringle IV
epeats (22,28). The Lp(a) levels are genetically determined,
nd therefore, OxPL/apoB levels tend to reflect this genetic
redisposition of Lp(a) levels.
Since the initial description of autoantibodies to OxLDL
pproximately 20 years ago (29–33), several concepts with
onsistent scientific evidence have emerged regarding auto-
ntibodies to OxLDL and apoB-immune complexes: 1)
hey are present in plasma of atherosclerotic animals and
atients with CVD. 2) They are also present in normal
ubjects of all ages, often with high titers. Interestingly,
hildren have been documented to have low levels of IgG
utoantibodies to OxLDL, which subsequently increase in
oung adulthood and older age. In contrast, IgM autoanti-
odies are higher earlier in life, but tend to decline during
lder age, when most CVD events occur (34–36); 3) The
gG and IgM autoantibody titers are not always highly
orrelated, and the same subjects may have high levels of
ne and low levels of the other. Female patients tend to have
igher levels of IgM autoantibodies than male patients. 4)
hey display an acute phase response in acutely ill patients,
ften increasing significantly within hours to days after an
vent. 5) They may have different influences on atherogen-
sis, at least in experimental models, in which IgMs, which
re more likely to be enriched in natural antibodies present
ven at birth (26) seem to be atheroprotective, but IgGs
eem to be atherogenic, except perhaps in response to
accination, in which they may be associated with athero-
rotection (10,26,34,35,37–39). In humans, we have re-
ently shown that IgM OxLDL autoantibodies and IgM
poB-ICs were associated inversely with the presence of
ngiographically determined CAD, whereas IgG OxLDL
utoantibodies and IgG apoB-ICs were positively associated
40). Consistent with prior studies in smaller numbers of
ubjects, this study showed higher MDA-LDL IgM levels
n female patients, patients 65 years of age, and nondia-
etic patients, and that younger patients also had higher
C/apoB IgM levels. Additionally, increased baseline levels
f IC/apoB IgM were previously shown to predict a reduced pisk of recurrent events in the MIRACL trial (3). Future
tudies evaluating such biomarkers will need to take into
ccount the age and sex of patients for proper comparison
nd interpretation, particularly in therapeutic studies (17).
The study also showed that both IgG and IgM autoan-
ibodies and IC measures tended to be higher in subjects
ith elevated apoB-100 or LDL-C levels. This finding is
ot surprising, because subjects with higher levels of such
ipoproteins would be more prone to generate OxLDL in
he vessel wall and other sites, which may potentiate an
mmune response to such oxidation-specific epitopes and
ugment such titers. Interestingly, there were no differences
n these measures when subjects were evaluated by median
igh-density lipoprotein cholesterol levels.
In prior smaller studies, atorvastatin prevented the ex-
ected increase in IgG OxLDL autoantibodies in patients
ith ACS (41), or led to overall reductions in levels in stable
atients (42). Other studies have not suggested an effect of
tatins on autoantibodies to OxLDL in children with
amilial hypercholesterolemia or in patients with hyperten-
ion (10,43). Another study with rosuvastatin had inconsis-
ent results (44). A limitation in interpreting these studies is
he lack of uniform evaluation with equipotent doses of
tatins in homogeneous populations. In the current study,
he expected increase in autoantibodies and ICs was also
oted, but there were no significant differences between
ubgroups or within subgroups in both the placebo and the
torvastatin groups.
xLDLbiomarkers as acute-phase reactants. The MIRACL
tudy represents the largest study in ACS subjects to
valuate the temporal relationship of OxLDL after cardio-
ascular events. Significant within-group increases in both
he placebo and the atorvastatin groups were generally
bserved in all autoantibody and ICs at the 16-week time
oint compared with baseline, but changes did not differ
mong the demographic and lipid-variable subgroups.
hese findings are consistent with several small studies that
ave shown a transient elevation in autoantibodies to
xLDL after ACS or percutaneous coronary intervention,
hich return to baseline over the next few hours, days, or
onths depending on the severity of the presentation
3,6,41,45,46).
elationship of oxidative biomarkers to inflammatory
nd thrombosis biomarkers. In the current analysis, we
howed very weak or no correlation between oxidative
iomarkers and C-reactive protein, serum amyloid A, tissue
lasminogen activator, interleukin-6, intercellular adhesion
olecule, vascular cell adhesion molecule, P-selectin, and
-selectin. Although the Spearman correlation coefficient
as statistically significant in some cases, this relates more
o large sample size than to strong correlation. In most
ases, 1% of the variability in inflammatory biomarkers
as explained by levels of oxidized lipid markers. However,
hese oxidative biomarkers correlate modestly to strongly
ith each other, suggesting that they have a distinct
athophysiological relationship in atherogenesis. In turn,
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June 9, 2009:2186–96 OxLDL, Inflammation, and Statin Therapyhe lack of correlation of the lipid and oxidized lipid
pitopes with C-reactive protein supports the view that
-reactive protein monitors an aspect of risk not reflected
y established or novel lipid markers.
tudy limitations. Because blood samples for biomarker
nalysis were not obtained at an intermediate time point
uring randomized treatment, the current analysis excludes
atients who died during the trial or did not provide a
6-week sample for other reasons. This study only included
ubjects with ACS treated with 1 dose of 1 statin, therefore
xtrapolation to all subjects with CVD or to treatment with
ther statins or different doses of atorvastatin should be
ade with this in mind. Because baseline blood samples
ere collected up to 4 days after admission to the hospital,
nd considering that lipoproteins and inflammatory biomar-
ers are acute-phase reactants, these values may not reflect a
rue physiologic baseline. This analysis was not pre-
pecified, and therefore the findings should be interpreted as
ypothesis generating until confirmed in a prospective
nalysis.
onclusions
n the current analysis, we show changes in OxLDL
iomarkers in response to statin therapy in large and specific
ubgroups of patients that have not been documented
reviously and provide insights into the interrelationships of
hese biomarkers to clinical, demographic, and inflamma-
ory variables. The consistent increase in OxPL/apoB, and
o a lesser extent Lp(a), in response to atorvastatin across all
ubgroups tested suggests that it may serve as a benchmark
or future studies evaluating such biomarkers. Future studies
re warranted to assess whether changes in these biomarkers
eflect therapeutic efficacy and predict clinical events.
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